TL Biolabs

Ever since the domestication of animals thousands of years ago, farmers have had a hand in the breeding of animals. But generally, this is done with a minimal amount of information like very basic knowledge about the parents.

It’s been a dream for decades that a deeper understanding of genetics would greatly enhance animal farming, but the cost has been too high. Current genomics tests — such as next-generation sequencing and SNP (single-nucleotide polymorphism) chips — are still too expensive… and will likely always be expensive given the fixed cost of the chemical reagents involved.

Aiming to make a huge impact into this space, TL Biolabs has developed a breakthrough in inexpensive genomics. They have created a novel genomics technique that greatly decreases the cost while maintaining the quality of the information gained. The upshot is that while current genomic tests are too expensive for the cost-driven dairy business, a high quality $15 test makes it possible for farmers to test every animal.

On top of the technology, they have a fantastic team: CEO Fred Turner was named UK Young Engineer in 2013 by The National Science + Engineering Competition for his early work developing novel technologies in genomics, and COO Sam Parlett and CIO Savvas Nicholas bring operational expertise and experience leading fast-paced software development teams. I’m excited to announce our investment in TL Biolabs and our partnership in ushering in a new era of low cost, genomics-driven precision farming.




The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation.

This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at

Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see for additional important information.

Biology is eating the world

Sign up for our bio newsletter to get the a16z take on the future of biology and engineering.